Keudell Viking Therapeutics, Inc. Call Options Transaction History
Keudell
- $341 Million
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding VKTX
# of Institutions
465Shares Held
65.4MCall Options Held
6.24MPut Options Held
2.97M-
Vanguard Group Inc Valley Forge, PA10.1MShares$741 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$442 Million0.01% of portfolio
-
State Street Corp Boston, MA5.12MShares$376 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.25MShares$165 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA1.86MShares$136 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $5.63B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...